Ipca
WHO / MMV Conference 2010
I
Ipca Laboratories Limited
Ipca
Ipca Laboratories LimitedPartnering Healthcare GloballyPartnering Healthcare Globally
Murali SarmaVi P id t &
2202/11/1002/11/10 22
Vice - President & Head Mission Malaria12-14th October 2010
IpcaIpca Overview Ipca Overview
Present Management since 1975USD 329Mn.
Total Income FY10USD 329Mn.
(22% top line growth)Exports FY10 USD 170Mn.
(50% of turnover)
Number of Employees 7,500+
F ll i t t d Ph
Business Model
Fully integrated Pharma company producing Branded & Generic Formulations & APIs
Business Mix 70% Formulations, 30% APIs
331
IpcaManufacturing FacilitiesManufacturing Facilities
Location Dosage Form Accreditations
Formulations Formulations –– 6 Locations 6 Locations –– Capacity Capacity -- 12 bln Tabs/ Caps12 bln Tabs/ Caps
Location Dosage Form Accreditations
Athal (Silvassa)
Tablets & Capsules WHO Geneva, UK MHRA, TGA Australia, MCC South Africa HPFB CanadaAfrica, HPFB Canada
Ratlam (M.P.) Tablets, Liquids & Inj. MCC South Africa Kandla (G j t)
Penicillin – Tablets, C l & D S
UK MHRA, (Gujarat) Capsules & Dry Syrups MCC South Africa, Silvassa Tablets & Capsules USFDA, UK MHRA,
TGA Australia, HPFB CanadaDehradun Tablets / Capsules,
Cephalosporin Inj.GMP
Indore (SEZ) Tablets & Capsules Being offered for WHO US &
44
Indore (SEZ) Tablets & Capsules Being offered for WHO, US & EU.
2
IpcaAthalAthal Formulation FacilityFormulation Facility
MajorCapacity 8 Bln TabletsCapacity 8 Bln Tablets
WHO Geneva
Major Accreditations
MHRA UKTGA AustraliaMCC South AfricaMCC South AfricaHPFB Canada
553
IpcaManufacturing Facilities
Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients –– 3 Locations 3 Locations –– 100 APIs 100 APIs
Location Capacity Accreditations
Ratlam 1800 MT p.a. WHO Geneva, USFDA,Ratlam 1800 MT p.a. WHO Geneva, USFDA, TGA Australia, EDQM, PMDA Japan,LAGeSo Berlin MOH
Indore 950 MT p.a. GMP
Aurangabad 600 MT p.a. GMPg p
664
IpcaRatlam API Facility
Over 55 DMFs filed with US FDA & over 30 CEPs
MajorAccreditationsAccreditationsWHO GenevaUSFDA LAG S B liLAGeSo Berlin MOHTGA AustraliaEDQMEDQM PMDA - Japan
One of the largest manufacturers of APIs like AmodiaquineOne of the largest manufacturers of APIs like Amodiaquine, Artemisinin Derivatives, Chloroquine, Atenolol, Propranolol, Metoprolol, Pyrantel Salts, Furosemide, Losartan & Hydroxy
775
Chloroquine Sulphate
IpcaIpca Credentials
• Among the top 10 pharma exporters from India
• India’s market leader in Anti-malarials in all dosage forms for over two decades.
• Over 30 years experience in manufacturing & marketing formulations.
• One of the world’s largest manufacturers of Artemisinin based APIs / Formulations.
Partnering Global F nd’s AMFm & VPP programmes• Partnering Global Fund’s AMFm & VPP programmes.
• 2 Formulations prequalified by WHO & 2 under evaluation.
886
IpcaMission Malaria
Committed to the cause of helping to save a million lives
WHO Geneva has approved our API & Formulation plantspp p
WHO Geneva has prequalified Ipca’s Artesunate 50mg +
Amodiaquine 153.1mg Co-blister Tablets and Artemether + q g
Lumefantrine 20/120mg Tablets
India’s market leader in antimalarials in all dosage forms – over g
30% market share
One of the World’s largest manufacturers of Artemisinin-based g
APIs & Formulations
997Contd…
IpcaMission MalariaTotal backward integration – from growing artemisinin annua crop to manufacturing APIs and Formulations
18% of current turnover from antimalarials – around US$60mln
Dedicated antimalarials division in India- special task force of 500 people
• Dr. Peter Weina from the Walter Reed Army Institute of Research –W hi t DC d t d l CME f I di D tWashington DC conducted several CMEs for Indian Doctors on malaria in May 2009
• One of the few WHO approved sources for Amodiaquine• One of the few WHO approved sources for Amodiaquine, Artesunate, Artemether & Lumefantrine (USDMF filed for all four)
• Dr. D.C. Jain is a renowned expert on artemisinin, has 23 patents &
1010
Dr. D.C. Jain is a renowned expert on artemisinin, has 23 patents & has published many papers on antimalarials.
8
IpcaProposition
Current scenario:
Orders under VPP and tenders from MOH are placed on oneOrders under VPP and tenders from MOH are placed on one supplier
Possible alternative scenario:Possible alternative scenario:
Orders can be placed on 2 to 3 qualified manufacturers with the quantity being dependent on the price and delivery conditions q y g p p yoffered
11119
IpcaBenefits
Benefits to Donors/ Purchaser:Risk of one supplier being unable to supply entire quantity is
d dreduced
Shorter lead time as 2 to 3 suppliers are involved
Though there may be no overall shortage, the person getting the order may not have adequate quantity of API
Benefits to approved manufacturers:Benefits to approved manufacturers:
With some surety of orders, manufacturers can keep stock of Artemisinin or API so that risk of late delivery is reduced
The company management can invest in high speed manufacturing and packing machines to reduce lead time as they can be sure of
d
1212
some orders
10
Ipca
MalariaMalaria –– a ruthless killera ruthless killer
A child dies every 30 seconds – 1 million lives lost annually to malariaA child dies every 30 seconds 1 million lives lost annually to malaria
500 million people affected and 40% of the world’s population is at risk
M f diM f di d t fl t M l id t fl t M l iMore fundingMore funding needs to flow to Malarianeeds to flow to Malaria
Falciparum M l i
T.B. HIVMalaria
Treatment Time 3 days 9 months Life Time
Risk of acute High if untreated Low LowRisk of acute mortality
High, if untreated Low Low
Cost of t t t
Cheaper than a b ttl f t
Costly Costliest
131311
treatment bottle of water
